Skip to content

Plaque Psoriasis, and The Efficacy Profile of Etanercept Treatment

Plaque Psoriasis, and The Efficacy Profile of Etanercept Treatment 1

To evaluate the efficacy and safety of etanercept treatment in adult patients with psoriasis after failure to respond to other previous therapies. In particular, the differences in efficacy profiles after switching from traditional (cyclosporine ciclosporin, methotrexate, retinoids, fumaric acid esters, psoralen plus UVA therapy, corticosteroids) or biologic (infliximab, efalizumab) treatments were analyzed. The study included 124 patients affected by plaque-type psoriasis who received etanercept administered subcutaneously at a dosage of 50 mg twice weekly for 12 weeks, followed by 25 mg twice weekly for an additional 12 weeks, and 110 patients affected by psoriatic arthritis who were treated with etanercept 25 mg twice weekly in a continuous regimen, after a 12-week period of treatment with etanercept 50 mg twice weekly. Long-term safety and efficacy of etanercept in the treatment of psoriasis. Several clinical trials support long-term use of etanercept, which was shown to have a good safety and efficacy profile. This was a retrospective, observational study of 43 patients with moderate to severe plaque psoriasis, with and without joint involvement, who received continuous treatment with etanercept for more than 24 weeks. It is characterized by well demarcated, erythematous plaques with an overlying silvery scale classically distributed on the extensor surfaces, scalp, and trunk, although it can affect any area of the skin (Figure 1). Long term etanercept efficacy in psoriasis.

The interleukin-17A inhibitor secukinumab was effective in the treatment of psoriasis, according to 2 large studies 2Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. The tumor necrosis factor (TNF) inhibitor etanercept has been demonstrated to be safe and effective for treating chronic plaque psoriasis in 3 clinical trials. In these integrated analyses, data for 1187 patients from 3 blinded treatment groups were pooled to compare efficacy at 12 weeks: etanercept 50 mg weekly (equivalent to 25 mg twice weekly) subcutaneously, etanercept 50 mg twice weekly subcutaneously, and placebo. Efficacy and safety of etanercept in the treatment of recalcitrant psoriasis: An open-label, retrospective, observational study in Taiwan. 50 mg) with a favorable safety profile during long-term therapy.

At week 24, after 12 weeks of open-label etanercept treatment, patients in the original placebo group had clinical benefits comparable to those of patients in the original etanercept group. 50 mg BIW, in patients with moderate to severe plaque psoriasis. Long-term Safety and Efficacy of Etanercept in the Treatment of Psoriasis. Several clinical trials support long-term use of etanercept, which was shown to have a good safety and efficacy profile. Material and methodsThis was a retrospective, observational study of 43 patients with moderate to severe plaque psoriasis, with and without joint involvement, who received continuous treatment with etanercept for more than 24 weeks. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. To observe the efficacy and safety profile of etanercept in patients with severe psoriasis resistant to other systemic agents over a 2-year period.

Efficacy Of Etanercept In An Integrated Multistudy Database Of Patients With Psoriasis

Objectives To compare the efficacy over 12 weeks of two different etanercept regimens in treating the skin manifestations of psoriasis in patients who also have psoriatic arthritis and to evaluate efficacy and safety over an additional 12 weeks of open label etanercept treatment. No new safety signals were seen in either etanercept treatment group, and no significant difference in the safety profiles was observed. Patients who had both moderate to severe plaque psoriasis and psoriatic arthritis were enrolled from 98 international sites into this randomised multicentre study. Etanercept, a tumour-necrosis-factor inhibitor, has shown efficacy in the treatment of rheumatoid arthritis. Etanercept was evaluated for the treatment of PsA and psoriasis in a preliminary study of 60 patients and in a confirmatory phase III study of 205 patients. Overall, etanercept is highly effective and well tolerated by patients with PsA, with a safety profile similar to that seen in rheumatoid arthritis. Elevated levels of TNF are found in the synovium and psoriatic plaques of patients with PsA. The primary arthritis efficacy response measure was the Psoriatic Arthritis Response Criteria (PsARC). PASI assesses treatment efficacy by measuring the reduction in redness, scaling and thickness of psoriatic plaques and the extent of involvement in each region of the body 5, 6. The extension study was conducted to collect long term efficacy, safety and tolerability data on Cosentyx in patients who achieved a PASI 75 response to Cosentyx at Week 52 of the FIXTURE and ERASURE core studies in moderate-to-severe plaque psoriasis. ETanercept Using 2 dosing Regimens to determine Efficacy in psoriasis) and ERASURE (Efficacy of Response And Safety of two fixed secUkinumab REgimens in psoriasis) are part of one of the largest Phase III program in moderate-to-severe plaque psoriasis completed to date, which involved more than 3,300 patients in over 35 countries 7. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Ustekinumab for chronic plaque psoriasis. The ACCEPT trial by Griffiths et al published in 2010 in the New England Journal of Medicine sought to compare the efficacy and safety profiles of etanercept, a TNF-alpha inhibitor and ustekinumab in the treatment of moderate-to-severe psoriasis. We evaluated the safety and efficacy of etanercept, a TNF antagonist, for the treatment of plaque psoriasis.

Jama Network

Etanercept is approved for the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis in adults. The PRESTA trial of bi-weekly dosing for 12 weeks then 50 mg once weekly reported that 70 of patients with moderate-to-severe chronic plaque psoriasis and psoriatic arthritis on etanercept achieved PASI 75 by week 24. Regular follow-up visits to monitor the safety and efficacy of treatment are also necessary. If there is active disease, TB treatment must be begun before initiation of the biologic. The safety profile of adalimumab in the plaque psoriasis clinical trials was reported to be similar to that seen in adalimumab clinical trials for rheumatoid arthritis. Psoriasis; Biological Agents; Efficacy; Safety; Health Technology Evaluation. Moreover, considering the current evidence about safety in RCTs, our findings show a similar safety profile among biologics in the short-term treatment and a result signalizing ustekinumab 45mg as the most well tolerated biological agent in the first three months of treatment. Etanercept treatment for children and adolescents with plaque psoriasis.